468 Studies Now Enrolling
A5332: Randomized Trial to Prevent Vascular Events in HIV REPRIEVE
REPRIEVE Trial to Prevent Heart Disease in HIV
| Sponsor: | NIH |
| Enrolling: | Male and Female Patients |
| Study Length: | 72 Months |
| Clinic Visits: | 12 |
| IRB Number: | AAAP0455 |
| U.S. Govt. ID: | NCT02344290 |
| Contact: | Anyelina Cantos: 212-305-6795 / ac4314@cumc.columbia.edu |
Additional Study Information:
Did you know that people living with HIV are 50-100% more likely to develop heart disease (including heart attack and stroke) than people without HIV? And did you know that women with HIV are 3 times more likely to have a heart attack than women without HIV? Heart disease in HIV-infected people is a big deal. We are doing a study to test if a daily dose of a statin (pitavastatin), a cholesterol-lowering medication, reduces the risk of heart disease in people living with HIV. The study is the first large-scale, randomized clinical research trial to test a strategy for heart disease prevention among people living with HIV. If you are between the ages of 40 and 75, on antiretroviral therapy for greater than 6 months and have no history of heart disease, you may be eligible.
This study is closed
Do You Qualify?
| Are you HIV positive? | Yes | No |
| Have you been taking anti-HIV medications for at least 6 months? | Yes | No |
| Do you have "high" levels of fat in the blood (Cholesterol) AND take medications for it? | Yes | No |
| Have you ever had any medical issues with your heart, including any surgical procedures? | Yes | No |
| Have you had any medical issues with your kidneys, including transplantation or have been on dialysis? | Yes | No |